Re: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

摘要

Recently, Wapnir et al. (1) provided detailed results of the long-term outcomes in ductal carcinoma in situ (DCIS) patients from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 and B-24 randomized trials. The data reported are very important because for every four diagnoses of invasive breast cancer, now there is one diagnosis of DCIS. However, understanding of the biology of DCIS and its interplay with the host microenvironment remains elusive (2).